U.S. pharma big copyright scrapped two experimental weight loss products last year—a when-each day capsule, lotiglipron, due to elevated liver enzymes and a two times-day-to-day tablet, danuglipron, due to potent Unintended effects—but CEO Albert Bourla has said the company is decide